High expression of SLC30A2-4, 8, and 10 was significantly associated with an unfavorable prognosis in stage I/III/IV, III, III/IV, I/III/IV, and I/III GC patients, respectively. This evidence concerns the gene SLC30A2 and gastric cancer.